Ginkgo Bioworks Holdings (DNA) said Thursday the Advanced Research Projects Agency for Health has awarded the company and its partners a $29 million contract for a project to stabilize and reshore supply chains for essential pharmaceuticals.
The company and its partners, Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals and Isolere Bio by Donaldson, will use wheat germ cell-free expression systems to develop distributed manufacturing of essential medicines under the two-year program, Ginkgo Bioworks said.
The strategy moves the production of active pharmaceutical ingredients to a "robust" and decentralized system from "fragile" global supply chains, the company said.
Price: 6.56, Change: -0.23, Percent Change: -3.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.